iCo Therapeutics, Inc.
iCo Therapeutics, Inc. is a biotechnology company, which focuses on the identification, development and commercialization of drug candidates that treat sight and life threatening diseases through a development-only business model. It has in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The company has three in-license product candidates: iCo-007, iCo-008 and Oral Amphotericin B Delivery System. iCo Therapeutics was founded by Andrew J. Rae, John G. Clement and William John Meekison on February 15, 2005 and is headquartered in Vancouver, Canada.